No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Sunshine Biopharma Files For Offering Of Mixed Shelf Of Up To $100M
Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target
Sunshine Biopharma Analyst Ratings
Unlock the Full List